Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
COSCIENS Biopharma Inc.
Toronto, Ontario, Canadacosciensbio.com ↗
- Ownership
- Public · AEZS
- Development stage
- Other
01
Overview
The company's lead product, macimorelin (Macrilen; Ghryvelin), is the first and only U.S. FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency (AGHD). The company is also developing several pipeline candidates including avenanthramides for inflammatory conditions and oat beta glucan for various applications.
- Therapeutic areas
- GastroenterologyCardiovascularEndocrinologyImmunologyOncologyNeurology
- Modalities
- Small moleculesDiagnostics
- Industry
- Biotech
02
Partnerships
Julius-Maximilians-University
Beyond the preview
Go deeper on COSCIENS Biopharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COSCIENS Biopharma Inc..